Нажмите на эту строку чтобы перейти к Новостям сайта "Русский врач"

Перейти
на сайт
журнала
"Врач"
Перейти на сайт журнала "Медицинская сестра"
Перейти на сайт журнала "Фармация"
Перейти на сайт журнала "Молекулярная медицина"
Перейти на сайт журнала "Вопросы биологической, медицинской и фармацевтической химии"
Журнал включен в российские и международные библиотечные и реферативные базы данных

ВАК (Россия)
РИНЦ (Россия)
Эко-Вектор (Россия)

POSSIBLE USE OF THE DRUGSECURITEL/VALSARTAN (OF APERIO)

DOI: https://doi.org/10.29296/25877313-2021-03-01
Download full text PDF
Issue: 
3
Year: 
2021

E.V. Okladnikova Ph.D (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Counseling with a Postgraduate Course, Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky (Krasnoyarsk, Russia) I.V. Gackich Ph.D (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Counseling with a Postgraduate Course, Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky (Krasnoyarsk, Russia) T.V. Potupchik Ph.D (Med.), Associate Professor, Department of Pharmacology and Pharmaceutical Counseling with a Postgraduate Course, Krasnoyarsk State Medical University named after Professor V. F. Voino-Yasenetsky (Krasnoyarsk, Russia) E-mail: potupchik_tatyana@mail.ru

In this article, a literature review of domestic and foreign sources on the use of the combined drug sacubitril/valsartan (uperio) was conducted, which showed that it can be used in patients suffering from CHF with a reduced ejection fraction of ≤40% and ≥45%. In the above sources, it is proved that the use of the drug securitel/valsartan (of aperio) leads to improved functional class of CHF and reduced requirements for diuretic therapy and improve tolerance to physical activity and quality of life of patients and reducing mortality from cardiovascular disease and admission to a hospital about CHF. The positive aspects of the use of the combination of sacubitril/valsartan in comorbid patients with chronic kidney disease and heart failure, even with a reduced ejection fraction in end-stage kidney disease, are shown. Sacubitril/valsartan may be recommended for use in patients with CHF and diabe-tes mellitus, taking into account the dose adjustment of hypoglycemic therapy. The data of studies on the use of sacubitril/valsartanau in patients with hypertension are presented, which confirm a good antihypertensive effect compared to other drugs for the treatment of elderly people suffering from systolic arterial hypertension and/or increased blood pressure mainly at night, resistant to drug therapy. Positive research results, as well as a good safety profile, indicate the possibility of using the drug sacubitril/valsartan in clinical practice.

Keywords: 
sacubitril/valsartan
chronic heart failure
hypertension
chronic kidney disease

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Hronicheskaja serdechnaja nedostatochnost'. Klinicheskie rekomendacii. 2020.
  2. Sitnikova M.Ju., Jurchenko A.V., Ljasnikova E.A., Truk¬shina M.A., Libis R.A., Kondratenko V.Ju., Dupljakov D.V., Hohlunov S.M., E. V. Shljahto E.V. Rezul'taty Ros-sijskogo gospital'nogo registra hronicheskoj serdechnoj nedostatochnosti v 3 sub’ektah Rossijskoj Federacii. Kardiologija, 2015;55(10):1321. DOI: 10.18565/cardio.2015.10.5-13
  3. Fomin I.V. Arterial'naja gipertonija v Rossijskoj Fe¬deracii – poslednie 10 let. Chto dal'she? Serdce: zhurnal dlja praktikujushhih vrachej. 2007; 6(3): 1–6.
  4. Fomin I.V. Jepidemiologija hronicheskoj serdechnoj nedos¬tatochnosti v Rossijskoj Federacii. V kn.: Ageev F.T. i dr. Hronicheskaja serdechnaja nedostatochnost'. M.: GJeOTAR-Media. 2010.
  5. Cleland J.G., Swedberg K., Follath F. Komajda M., Cohen-Solal A., Aguilar J.C., Dietz R., Gavazzi A., Hobbs R., Korewicki J., Madeira H.C., Moiseyev V.S., Preda I., van Gilst W..H, Widimsky J., Freemantle N., Eastaugh J. The EuroHeart Failure survey programme a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24 (5):442–463.DOI:10.1016/s0195-668x(02)00823-0.
  6. Ageev F.T., Danieljan M.O., Mareev V.Ju., Belenkov Ju.N. Bol'nye s hronicheskoj serdechnoj nedostatochnost'ju v rossijskoj ambulatornoj praktike: osobennosti kontin¬genta, diagnostiki i lechenija (po materialam issledova¬nija JePOHA–O–HSN). Serdechnaja nedostatochnost' 2004; 5(1):4–7.
  7. Danieljan M.O. Prognoz i lechenie hronicheskoj serdech¬noj nedostatochnosti (dannye 20-i letnego nabljudenija): Avtoref. diss. …. kand. med. nauk. M. 2001.
  8. Fomin I.V.,Belenkov Ju.N., Mareev V.Ju., Ageev F.T., Badin Ju.V., Galjavich A.S., Danieljan M.O., Kamalov G.M., Kolbin A.A., Kechedzhieva S.G., Makarova V.G., Makarova N.V., Malenkova V.Ju., Sajfutdinov R.I., Tarlovskaja E.I., Hohlov R.A., Shherbinina E.V., Jakushin S.S. Rasprostranennost' hronicheskoj serdechnoj ne-dostatochnosti v Evropejskoj chasti Rossijskoj Federacii – dannye JePOHA –HSN. Serdechnaja nedostatochnost'. 2006; 7(1):112–115.
  9. Badin Ju.V., Fomin I.V. Vyzhivaemost' bol'nyh HSN v kogortnoj vyborke Nizhegorodskoj oblasti (dannye 1998–2002 godov.). Vserossijskaja konferencija OSSN: Ser-dechnaja nedostatochnost'. 2005. M. 2005.
  10. Jakushin S.S., Smirnova E.A., Liferov R.A. Vyzhiva¬emost' bol'nyh hronicheskoj serdechnoj nedostatoch¬nost'ju (dannye kogortnogo issledovanija reprezentativnoj vyborki naselenija Rjazanskoj oblasti). Serdechnaja nedostatochnost'. 2011; 12(4):218-221.
  11. Fomin I.V. Hronicheskaja serdechnaja nedostatochnost' v Rossijskoj federacii: chto segodnja my znaem i chto dolzhny delat'. Rossijskij kardiologicheskij zhurnal. 2016; (8):7-13.https://doi.org/10.15829/1560-4071-2016-8-7-13.
  12. Lam C.S.P., Solomon S.D. The middle child in heart failure: heart failure with mid-range ejection fraction (40–50%). Eur. J. Heart Fail. 2014; 16:1049–1055. DOI:10.1002/ejhf.159.
  13. Tereshhenko S.N., Zhirov I.V., Narusov O.Ju., Mareev Ju.V., Zatejshhikov D.A., Osmolovskaja Ju.F., Ovchinnikov A.G., Samko A.N., Nasonova S.N., Stukalova O.V., Saidova M.A., Skvorcov A.A., Sharija M.A., Javelov I.S. Diagnostika i lechenie hronicheskoj i ostroj serdechnoj nedostatoch-nosti. Kardiologicheskij vestnik. 2016; 2:3-33.
  14. Chen J., Normand S.L., Wang Y., Krumholz H.M. National and regional trends in heart failure hospitalization and mortality rates for Medicare beneficiaries, 1998–2008. JAMA. 2011; 306(15):1669–1678.DOI:10.1001/jama.2011.1474.
  15. Dunlay S.M., Redfield M.M., Weston S.A., Therneau T.M., Long K.H., Shah N.D., Roger V.L. Hospitalizations after heart failure diagnosis a community perspective. J. Am.Coll. Cardiol. 2009; 54 (18):1695–1702.
  16. Mc Murray J. Clinical practice. Systolic heart failure. N. Engl. J. Med. 2010; 362(3):228–238. DOI:10.1056/NEJMcp0909392.
  17. Mant J., Doust J., Roalfe A., Barton P., Cowie M.R., Glasziou P., Mant D., McManus R.J., Holder R., Deeks J., Fletcher K., Qume M., Sohanpal S., Sanders S., Hobbs F.D.R. Systematic review and individual patient data meta-analysis of diagnosis of heart failure, with modelling of implications of different diagnostic strategies in primary care. Health Technol. Assess. 2009; 13:1–207.
  18. Dimopoulos K., Saukhe T.V., Coats A., Mayet J., Piepoli M., Francis D.P. Meta-analyses of mortality and morbidity effects of an angiotensin receptor blocker in pa-tients with chronic heart failure already receiving an ACE inhibitor (alone or with a beta-blocker). Int. J.Cardiol. 2004; 93(2–3):105-111.
  19. Maggioni A.Р., Anand I., Gottlieb S.O., et al. Effects of Valsartan on Morbidity and Mortality in Patients With Heart Failure Not Receiving Angiotensin-Converting En-zyme inhibitors. J. Am. Coll. Cardiol. 2002; 40(8):1414–1421.
  20. Pfeffer M.A., McMurray J.J., Velazquez E.J., Rouleau J.-L., Køber L.,Maggioni A.P., Solomon S.D., Swedberg K., Van de WerfF., White H., Leimberger J.D., Henis M., Edwards S., Zelenkofske S., Sellers M.A., Califf R.M. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N. Engl. J. Med. 2003; 349(20):1893–1906.DOI:10.1056/NEJMoa032292.
  21. Velazquez E.J., Morrow D.A., DeVore A.D., Duffy C.I., Ambrosy A.P., McCague K., Rocha R., Braunwald E. PIONEER-HF Investigators. Angiotensin–Neprilysin Inhibition in Acute Decompensated Heart Failure. N. Engl. J. Med. 2019; 380(6):539-548. DOI: 10.1056/NEJMoa1812851.
  22. Yusuf S., Pitt B., Davis C.E., Hood W.B., Cohn J.N. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD investigators. N. Engl. J. Med. 1991; 325 (5):293–302. DOI: 10.1056/NEJM199108013250501.
  23. Mc Murray J.J., Packer M., Desai A.S., Gong J., Lefkowitz M.P., Rizkala A.R., Rouleau J.L., Shi V.C., Solomon S.D., Swedberg K., Zile M.R. PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N. Engl. J. Med. 2014; 371:993–1004.
  24. Kałużna-Oleksy M., Kolasa J., Migaj J., Pawlak A., Lelonek M., Nessler J., Straburzyńska-Migaj Е. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland. Kardiol. Pol. 2018; 76:381–387. DOI:10.1002/ejhf.1498.
  25. Pogge E.K., Davis L.E. Evaluating the safety and tolerability of sacubitril/valsartan for HFrEF managed within a pharmacist clinic. Am J. Cardiovasc. Drugs. 2018; 18:143–151.DOI:10.1007/s40256-018-0264-5.
  26. Wachter R., Viriato D., Klebs S., Grunow S.S., Schindler M., Engelhard J., Proenca C.C., Calado F., Schlienger R., Dworak M., Balas B., Wirta S.B. Early insights into the characteristics and evolution of clinical parameters in a cohort of patients prescribed sacubitril/valsartan in Germany. Postgrad Med. 2018; 130:308–316. DOI:10.1080/00325481.2018.1442090.
  27. Haddad H., Bergeron S., Ignaszewski A., Searles G., Rochdi D., Dhage P., Bastien N. Canadian Real-World Experience of Using Sacubitril/Valsartan in Patients With Heart Failure With Reduced Ejection Fraction: Insight From the PARASAIL Study. CJC Open. 2020; 2(5): 344-353. DOI:10.1016/j.cjco.2020.04.007.
  28. Solomon S.D., Rizkala A.R., Gong J., Wang W., Anand I.S., Ge J., Lam C.S.P., Maggioni A..P, Martinez F., Packer M., Pfeffer M.A., Pieske B., Redfield M.M., Rouleau J.L., Van Veldhuisen D.J., Zannad F., Zile M.R., Desai A.S., Shi V.C., Lefkowitz M.P., McMurray J.J.V. Angiotensin Receptor Nepri¬lysin Inhibition in Heart Failure with Preserved Ejection Frac¬tion: Rationale and Design of the PARAGON-HF Trial. JACC Heart Fail. 2017; 5(7):471-482. DOI:10.1016/j.jchf.2017.04.013.
  29. Vaduganathan M., Jhund P.S., Claggett B.L., Packer M., Widimský J., Seferovic P., Rizkala A., Lefkowitz M., Shi V., McMurray J.J.V., Solomon S.D. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction. Eur. Heart J. 2020; 41(25):2356-2362. DOI:10.1093/eurheartj/ehaa184.
  30. Robles N.R., Campillejo R.D., Valladares J., de Vinuesa E.G., Villa J., Gervasini G. Sacubitril-Valsartan Improves Anemia of Cardiorenal Syndrome. Cardiovasc. Hema-tol. Agents Med. Chem. 2020 May 5. DOI: 10.2174/1871525718666200506095537.
  31. Lee S., Oh J., Kim H., Ha J., Chun K.H., Lee C.J., Park S., Lee S.H., Kang S.M. Sacubitril/valsartan in patients with heart failure with reduced ejection fraction with end-stage of renal disease. ESC Heart Fail. 2020; 7(3): 1125-1129. DOI:10.1002/ehf2.12659. Kario K. The Sacubitril/Valsartan, a First-in-Class, Angio¬tensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Curr. Cardiol. Rep. 2018; 20(1):5. DOI:10.1007/s11886-018-0944-4
  32. Seferovic J.P., Claggett B., Seidelmann S.B., Seely E.W., Packer M, Zile M.R., Rouleau J.L., Swedberg K., Lefkowitz M., Shi V.C., Desai A.S., McMurray J.J.V., Solomon S.D. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Lancet Diabetes Endocrinol. 2017; 5(5):333-340. DOI:10.1016/S2213-8587(17)30087-6.
  33. Kario K. The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond. Curr. Cardiol. Rep. 2018; 20(1):5. DOI:10.1007/s11886-018-0944-4.
  34. Norberg H, Bergdahl E, Lindmark K. Safety and Tolerability of Initiating Maximum-Dose Sacubitril-Valsartan in Patients on Target Dose Renin-Angiotensin System In-hibitors. Cardiovasc. Ther. 2019 Aug 1; 2019: 6745074. DOI:10.1155/2019/6745074.
  35. Supasyndh O., Wang J., Hafeez K., Zhang Y., Zhang J., Rakugi H. Efficacy and Safety of Sacubitril/Valsartan (LCZ696) Compared with Olmesartan in Elderly Asian Patients (≥65 years) with Systolic Hypertension. Am J. Hypertens. 2017; 30(12):1163-1169. DOI:10.1093/ajh/hpx111.
  36. Cheung D.G., Aizenberg D., Gorbunov V., Hafeez K., Chen C.W., Zhang J. Efficacy and safety of sacubitril/valsartan in patients with essential hypertension uncon-trolled by olmesartan: A randomized, double-blind, 8-week study. J Clin. Hypertens. (Greenwich). 2018; 20(1):150-158. DOI:10.1111/jch.13153.
  37. Haynes R., Judge P.K., Staplin N., Herrington W.G., Storey B.C., Bethel A., Bowman L., Brunskill N., Cockwell P., Hill M., Kalra P.A., McMurray J.J.V., Taal M., Wheeler D.C., Landray M.J., Baigent C. Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease. Circulation. 2018; 138(15):1505-1514. DOI:10.1161/CIR¬CULATIONAHA.118.034818.
  38. Desai A.S., Mc Murray J.J., Packer M., Swedberg K., Rouleau J.L., Chen F., Gong J., Rizkala A.R., Brahimi A., Claggett B., Finn P.V., Hartley L.H., Liu J., Lefkowitz M., Shi V., Zile M.R., Solomon S.D. Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with ena¬lapril on mode of death in heart failure patients. Eur. Heart. J. 2015; 36(30):1990-1997. DOI:10.1093/eurheartj/ehv186.
  39. Gan L., Langenickel T., Petruck J, Kode K., Rajman I., Chandra P., Zhou W., Rebello S., Sunkara G. Effects of age and sex on the pharmacokinetics of LCZ696, an angiotensin receptor neprilysin inhibitor. J. Clin. Pharmacol. 2016; 56(1): 78-86. DOI: 10.1002/jcph.571.
  40. Shi V., Senni M., Streefkerk H., Modgill V., Zhou W., Kaplan A. Angioedema in heart failure patients treated with sacubitril/valsartan (LCZ696) or enalapril in the PARADIGM-HF study. Int. J. Cardiol. 2018; 264:118-123. DOI:10.1016/j.ijcard.2018.03.121.
  41. Gosudarstvennyj reestr lekarstvennyh sredstv [Jelektronnyj resurs] Rezhim dostupa http://grls.rosminzdrav.ru